Dashboard
Manage Tickers

IMRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immuneering-q3-eps-038-beats-039-estimate
Immuneering Q3 EPS $(0.38) Beats $(0.39) E...
11/12/2025 21:06:57

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) b...

earnings-scheduled-for-november-12-2025
Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

a-preview-of-immuneerings-earnings
A Preview Of Immuneering's Earnings
11/11/2025 15:03:44

this-immuneering-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Immuneering Analyst Begins Coverage O...
10/31/2025 11:29:02

leerink-partners-initiates-coverage-on-immuneering-with-outperform-rating-announces-price-target-of-15
Leerink Partners Initiates Coverage On Imm...
10/31/2025 11:02:57

Leerink Partners analyst Andrew Berens initiates coverage on Immuneering (NASDAQ:IMRX) with a Outperform rating and announce...

hc-wainwright--co-reiterates-buy-on-immuneering-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
09/30/2025 11:43:59

HC Wainwright & Co. analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $11 price target.

immuneering-to-host-call-on-september-29-2025-at-830-am-et-to-discuss-updated-survival-and-safety-data-for-atebimetinib--mgnp-in-first-line-pancreatic-cancer
Immuneering To Host Call On September 29, ...
09/26/2025 20:01:59

Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today annou...

chardan-capital-maintains-buy-on-immuneering-raises-price-target-to-20
Chardan Capital Maintains Buy on Immuneeri...
09/26/2025 11:36:16

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ: IMRX) with a Buy and raises the price target from $13...

oppenheimer-maintains-outperform-on-immuneering-raises-price-target-to-30
Oppenheimer Maintains Outperform on Immune...
09/25/2025 13:57:47

Oppenheimer analyst Jay Olson maintains Immuneering (NASDAQ: IMRX) with a Outperform and raises the price target from $21 to...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/25/2025 12:08:49

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket
Why PepGen Shares Are Trading Higher By 11...
09/25/2025 10:11:08

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

Core News & Articles
Immuneering Prices $175M Underwritten Publ...
09/25/2025 06:17:13

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 21:06:04

Core News & Articles
Immuneering Announces Public Offering And ...
09/24/2025 20:11:35

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announ...

immuneering-announces--updated-survival-and-safety-data-from-its-ongoing-phase-2a-trial-of-atebimetinib-in-combination-with-modified-gemcitabinenab-paclitaxel-in-first-line-pancreatic-cancer-patients-with-9-months-median-follow-up--86-overall-survival-observed-at-9-months-co-expects-regulatory-feedback-on-pivotal-trial-plans-in-q4-2025-and-subject-to-that-feedback-expects-to-initiate-pivotal-trial-by-the-end-of-2025-and-begin-dosing-patients-by-mid-2026
Immuneering Announces Updated Survival An...
09/24/2025 20:04:41

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused o...

immuneering-names-thomas-schall-chairman-of-the-board-replaces-ben-zeskind-in-leadership-transition
Immuneering Names Thomas Schall Chairman O...
09/16/2025 11:12:13

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announ...

needham-maintains-buy-on-immuneering-raises-price-target-to-11
Needham Maintains Buy on Immuneering, Rais...
09/15/2025 10:48:21

Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $8 to $11.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 17:07:06

biotech-firm-immuneering-plans-key-cancer-data-presentations-at-upcoming-boston-summits
Biotech Firm Immuneering Plans Key Cancer ...
09/10/2025 11:12:27

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared...

needham-reiterates-buy-on-immuneering-maintains-8-price-target
Needham Reiterates Buy on Immuneering, Mai...
08/26/2025 10:25:30

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $8 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION